export const dummyData = {
  name: "V940 (mRNA-4157)",
  indication: "High-risk resected melanoma",
  platform: "mRNA",
  trial: {
    phase: 3,
    identifier: "NCT05933577",
    status: "Recruiting",
    start_date: "2023-07-01",
    primary_completion_date: "2026-12-31",
    locations: ["US", "EU", "AU"],
    participants_enrolled: 1075,
    key_endpoints: ["Recurrence-free survival", "Overall survival"],
    latest_update: "2025-04-15T10:45:00Z",
  },
  science_highlights: [
    {
      date: "2024-11-15",
      summary:
        "Phase 2 data showed a reduction in melanoma recurrence from 40% to 22% when mRNA-4157 was added to pembrolizumab, prompting global phase 3 validation. Phase 2 data showed a reduction in melanoma recurrence from 40% to 22% when mRNA-4157 was added to pembrolizumab, prompting global phase 3 validation.",
    },
  ],
  investments: {
    lead_sponsor: "Moderna",
    invested_companies: [
      {
        name: "Moderna",
        money_invested_usd: 530000000,
        years_active: [2019, 2020, 2021, 2022, 2023, 2024, 2025],
      },
      {
        name: "Merck & Co., Inc.",
        money_invested_usd: 200000000,
        years_active: [2022, 2023, 2024, 2025],
      },
    ],
    total_money_over_last_10_years_usd: [
      0, 0, 0, 0, 0, 50000000, 100000000, 150000000, 250000000, 330000000,
    ],
  },
  market_outlook: {
    estimated_peak_sales_usd: 3400000000,
    expected_launch_year: 2027,
    competitive_landscape: ["BioNTech - BNT111", "Gritstone - GRANITE"],
  },
  tags: [
    "immuno-oncology",
    "vaccine",
    "phase 3",
    "melanoma",
    "Moderna",
    "Merck",
  ],
  last_synced: "2025-05-21T12:30:00Z",
};
